{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T11:22:34Z","timestamp":1767871354869,"version":"3.49.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral nerve palsy is a prevalent clinical condition that significantly impairs patients\u2019 quality of life. To advance clinical practice and mitigate the risk of drug-induced peripheral nerve palsy, this study aimed to identify adverse drug reaction signals related to peripheral nerve palsy through data mining of the FDA Adverse Event Reporting System (FAERS). Timely detection of high-risk medications provides a crucial basis for enhancing the safety of clinical drug use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse events (AEs) related to peripheral nerve palsy between 2004 and the third quarter of 2024 were extracted from the FAERS database. To identify potential drug safety signals associated with peripheral nerve palsy, four established pharmacovigilance statistical methods were employed: the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Multi-Item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5,787 reports of drug-associated peripheral nerve palsy adverse events involving 1,141 drugs were identified in this analysis. Among these, natalizumab had the highest number of reported cases, followed by interferon beta-1a and dalfampridine. The most commonly implicated drug classes were antineoplastic drugs and immunosuppressants. A total of 30 drugs exhibited positive risk signals, of which 19 met the criteria for a positive signal across all four analytical algorithms. Notably, both the ROR and BCPNN methods indicated that bupivacaine, dalfampridine, natalizumab, minocycline, and ocrelizumab are among the high-risk drugs associated with peripheral nerve palsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified that several medications, including bupivacaine, dalfampridine, natalizumab, minocycline, and ocrelizumab, are significantly associated with an increased risk of peripheral nerve palsy. These findings contribute to a deeper understanding of drug safety profiles, support the promotion of rational medication use, and provide valuable insights to inform clinical decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1691263","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:33:58Z","timestamp":1767854038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingjie","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueliang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nengwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/14740338.2017.1335304","article-title":"Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation","volume":"17","author":"Aggarwal","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.12.026","article-title":"Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: randomized, double-blind, placebo-controlled clinical trial. Preliminary report","volume":"28","author":"Arreola-Mora","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B3","first-page":"1131","article-title":"Isoniazid induced motor-dominant neuropathy","volume":"65","author":"Arsalan","year":"2015","journal-title":"J. Pak Med. Assoc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1212\/NXI.0000000000000180","article-title":"Vasculitic neuropathy following exposure to minocycline","volume":"3","author":"Baratta","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/157488609789006949","article-title":"Adverse effects of statins - mechanisms and consequences","volume":"4","author":"Be\u0142towski","year":"2009","journal-title":"Curr. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-0035-1553475","article-title":"Chemotherapie-induzierte polyneuropathie [chemotherapy-induced peripheral neuropathy]","volume":"83","author":"Bobylev","year":"2015","journal-title":"Fortschr Neurol. Psychiatr."},{"key":"B7","first-page":"732","article-title":"Peripheral neuropathy: evaluation and differential diagnosis","volume":"102","author":"Castelli","year":"2020","journal-title":"Am. Fam. Physician"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1473756","DOI":"10.3389\/fphar.2024.1473756","article-title":"Disproportionality analysis of oesophageal toxicity associated with oral bisphosphonates using the FAERS database (2004-2023)","volume":"15","author":"Chen","year":"","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1345811","DOI":"10.3389\/fnmol.2024.1345811","article-title":"Current understanding of the molecular mechanisms of chemotherapy-induced peripheral neuropathy","volume":"17","author":"Chen","year":"","journal-title":"Front. Mol. Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41598-024-84679-4","article-title":"Real world pharmacovigilance assessment of drug related macular degeneration risks","volume":"15","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/AJP.0000000000000293","article-title":"Sciatic nerve intrafascicular lidocaine injection-induced peripheral neuropathic pain: alleviation by systemic minocycline administration","volume":"32","author":"Cheng","year":"2016","journal-title":"Clin. J. Pain"},{"key":"B12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40263-021-00822-z","article-title":"Interferons and multiple sclerosis: lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (avonex)","volume":"35","author":"Cohan","year":"2021","journal-title":"CNS Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1345\/aph.1Z429","article-title":"Peripheral neuropathy associated with fluoroquinolones","volume":"35","author":"Cohen","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e733","DOI":"10.1212\/WNL.0000000000007970","article-title":"Effect of dalfampridine on information processing speed impairment in multiple sclerosis","volume":"93","author":"De Giglio","year":"2019","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1136\/jnnp-2020-323124","article-title":"Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies","volume":"91","author":"Fargeot","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD002086","DOI":"10.1002\/14651858.CD002086.pub2","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"2012","author":"Garner","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann. Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1191\/1352458505ms1209oa","article-title":"Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis","volume":"11","author":"Herndon","year":"2005","journal-title":"Mult. Scler."},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40263-018-0586-5","article-title":"Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, phase III enhance trial of prolonged-release fampridine","volume":"33","author":"Hobart","year":"2019","journal-title":"CNS Drugs"},{"key":"B23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/1352458515581436","article-title":"Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial","volume":"22","author":"Hupperts","year":"2016","journal-title":"Mult. Scler."},{"key":"B24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/AAP.0000000000000283","article-title":"Safety and side effect profile of liposome bupivacaine (exparel) in peripheral nerve blocks","volume":"40","author":"Ilfeld","year":"2015","journal-title":"Reg. Anesth. Pain Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1213\/ANE.0000000000002186","article-title":"Diphenyleneiodonium mitigates bupivacaine-induced sciatic nerve damage in a diabetic neuropathy rat model by attenuating oxidative stress","volume":"125","author":"Ji","year":"2017","journal-title":"Anesth. Analg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1574884714666190121154813","article-title":"Drug-induced peripheral neuropathy: a narrative review","volume":"15","author":"Jones","year":"2020","journal-title":"Curr. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/CND.0000000000000197","article-title":"Peripheral vasculitic neuropathy associated with minocycline use","volume":"19","author":"Kang","year":"2018","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in multiple sclerosis treatment: from biological effects to immune monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5507\/bp.2022.022","article-title":"Ethambutol-induced optic neuropathy","volume":"167","author":"Kyncl","year":"2023","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc Czech Repub."},{"key":"B31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8539026","DOI":"10.1155\/2017\/8539026","article-title":"Activation of p47phox as a mechanism of bupivacaine-induced burst production of reactive oxygen species and neural toxicity","volume":"2017","author":"Li","year":"2017","journal-title":"Oxid. Med. Cell Longev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neuro.2020.10.004","article-title":"Vincristine-induced peripheral neuropathy: a mini-review","volume":"81","author":"Li","year":"2020","journal-title":"Neurotoxicology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/14740338.2023.2278700","article-title":"Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2448833","article-title":"Gabapentinoids related psychiatric disorders: an analysis based on the FAERS database from 2004 to 2023","volume":"3","author":"Li","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1213\/ane.0b013e318168514b","article-title":"In vitro, inhibition of mitogen-activated protein kinase pathways protects against bupiva-caine- and ropivacaine-induced neurotoxicity","volume":"106","author":"Lirk","year":"2008","journal-title":"Anesth. Analg."},{"key":"B37","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/DDDT.S192225","article-title":"Monosialoganglioside protects against bupivacaine-induced neurotoxicity caused by endoplasmic reticulum stress in rats","volume":"13","author":"Liu","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e16285","DOI":"10.1111\/ene.16285","article-title":"Rate and characteristics of inflammatory neuropathies associated with brentuximab vedotin therapy","volume":"31","author":"Matthys","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19400","article-title":"Peripheral neuropathy: a review","author":"Mauermann","year":"2025","journal-title":"JAMA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4314\/eamj.v83i1.9362","article-title":"The role of neuro-electrophysiological diagnostic tests in clinical medicine","volume":"83","author":"Mbuya","year":"2006","journal-title":"East Afr. Med. J."},{"key":"B41","first-page":"11","article-title":"Neurologic conditions: common peripheral neuropathies","volume":"477","author":"McKinley","year":"2019","journal-title":"FP Essent."},{"key":"B42","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4161\/cc.27476","article-title":"Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy","volume":"13","author":"Meregalli","year":"2014","journal-title":"Cell Cycle"},{"key":"B43","doi-asserted-by":"publisher","first-page":"103995","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B44","doi-asserted-by":"publisher","first-page":"CD006097","DOI":"10.1002\/14651858.CD006097.pub3","article-title":"Natalizumab for induction of remission in Crohn's disease","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1080\/14740338.2016.1179277","article-title":"A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma","volume":"15","author":"Oak","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5692\/clinicalneurol.50.301","article-title":"Case of minocycline-induced vasculitic neuropathy","volume":"50","author":"Ogawa","year":"2010","journal-title":"Rinsho Shinkeigaku"},{"key":"B47","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/1060028020939926","article-title":"Minocycline topical foam: a new drug for the treatment of acne","volume":"55","author":"Onge","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/14737175.2016.1169924","article-title":"Natalizumab in relapsing-remitting multiple sclerosis","volume":"16","author":"Outteryck","year":"2016","journal-title":"Expert Rev. Neurother."},{"key":"B49","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/00019052-200210000-00015","article-title":"Recent advances in drug-induced neuropathies","volume":"15","author":"Peltier","year":"2002","journal-title":"Curr. Opin. Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1345\/aph.1Q714","article-title":"Dalfampridine: a medication to improve walking in patients with multiple sclerosis","volume":"46","author":"Pikoulas","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000489303","article-title":"Severe acute axonal neuropathy induced by ciprofloxacin: a case report","volume":"10","author":"Popescu","year":"2018","journal-title":"Case Rep. Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.36518\/2689-0216.1400","article-title":"Ciprofloxacin-induced peripheral neuropathy: a case report","volume":"4","author":"Refaeian","year":"2023","journal-title":"HCA Healthc. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/ejhpharm-2019-002048","article-title":"Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis","volume":"28","author":"Rodr\u00edguez de Castro","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1441147","DOI":"10.3389\/fphar.2024.1441147","article-title":"Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement","volume":"15","author":"Sankar","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00277-024-06121-z","article-title":"The efficacy and safety of nelarabine in relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"104","author":"Shakeel","year":"2025","journal-title":"Ann. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/20469047.2018.1482996","article-title":"Isoniazid-induced neuropathy in a pre-pubertal child","volume":"39","author":"Shetty","year":"2019","journal-title":"Paediatr. Int. Child. Health"},{"key":"B57","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.amjoto.2005.02.019","article-title":"Peripheral facial nerve paralysis after peritonsillar infiltration of bupivacaine: a case report","volume":"26","author":"Shlizerman","year":"2005","journal-title":"Am. J. Otolaryngol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.2174\/1874467214666210210122628","article-title":"Minocycline and doxycycline: more than antibiotics","volume":"14","author":"Singh","year":"2021","journal-title":"Curr. Mol. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"113121","DOI":"10.1016\/j.expneurol.2019.113121","article-title":"Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems","volume":"324","author":"Staff","year":"2020","journal-title":"Exp. Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cts.12915","article-title":"Role for drug transporters in chemotherapy-induced peripheral neuropathy","volume":"14","author":"Stage","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3389\/fnins.2019.00653","article-title":"Minocycline prevents the development of mechanical allodynia in mouse models of vincristine-induced peripheral neuropathy","volume":"13","author":"Starobova","year":"2019","journal-title":"Front. Neurosci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1626909","DOI":"10.3389\/fneur.2025.1626909","article-title":"Ethambutol optic neuropathy","volume":"16","author":"Sudhakar","year":"2025","journal-title":"Front. Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bpa.2014.02.001","article-title":"Liposomal bupivacaine and clinical outcomes","volume":"28","author":"Tong","year":"2014","journal-title":"Best. Pract. Res. Clin. Anaesthesiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/ijms22084112","article-title":"Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment","volume":"22","author":"Triarico","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.3390\/cancers13236125","article-title":"Brentuximab-induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in hodgkin lymphoma therapy","volume":"13","author":"Velasco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1080\/0284186X.2021.1954241","article-title":"Neuro-immune interactions in paclitaxel-induced peripheral neuropathy","volume":"60","author":"Vermeer","year":"2021","journal-title":"Acta Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bcpt.12261","article-title":"Drug-induced peripheral neuropathy","volume":"115","author":"Vilholm","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2147\/DDDT.S196172","article-title":"Tetramethylpyrazine attenuated bupivacaine-induced neurotoxicity in SH-SY5Y cells through regulating apoptosis, autophagy and oxidative damage","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1529260","DOI":"10.3389\/fphar.2024.1529260","article-title":"Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS","volume":"15","author":"Wang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/ijms22020888","article-title":"Pathological mechanisms of bortezomib-induced peripheral neuropathy","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.biopha.2017.07.078","article-title":"Minocycline attenuates the development of diabetic neuropathy by inhibiting spinal cord Notch signaling in rat","volume":"94","author":"Yang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7224\/1537-2073.2014-040","article-title":"Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis: a randomized controlled trial","volume":"17","author":"Yapundich","year":"2015","journal-title":"Int. J. MS Care"},{"key":"B74","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"B75","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B76","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1053\/j.seminoncol.2021.09.004","article-title":"Chemotherapy-induced peripheral neuropathy and rehabilitation: a review","volume":"48","author":"Zhang","year":"2021","journal-title":"Semin. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13023-021-01694-8","article-title":"Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/pmic.201500202","article-title":"iTRAQ proteomics analysis reveals that PI3K is highly associated with bupivacaine-induced neurotoxicity pathways","volume":"16","author":"Zhao","year":"2016","journal-title":"Proteomics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1691263\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:34:01Z","timestamp":1767854041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1691263\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":79,"alternative-id":["10.3389\/fphar.2025.1691263"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1691263","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1691263"}}